- Home
- IDCC vs LEGN Comparison
IDCC vs LEGN Comparison
Compare IDCC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDCC | LEGN |
|---|---|---|
| Founded | 1972 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.9B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IDCC | LEGN |
|---|---|---|
| Price | $337.94 | $21.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $412.50 | $61.33 |
| AVG Volume (30 Days) | 165.9K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $307,404,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | $3.38 | $30.52 |
| P/E Ratio | $60.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $249.14 | $16.24 |
| 52 Week High | $412.60 | $37.50 |
Technical Indicators
Market Signals| Indicator | IDCC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 51.95 |
| Support Level | $330.55 | $20.70 |
| Resistance Level | $336.25 | $21.97 |
| Average True Range (ATR) | 10.68 | 1.00 |
| MACD | -3.87 | 0.24 |
| Stochastic Oscillator | 54.98 | 57.84 |
Price Performance
Historical ComparisonAbout IDCC InterDigital Inc.
InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.